The insulin-like growth factor-I receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis

Critical Reviews in Oncogenesis

Volumn 8, Issue 1, 1997, Pages 71-92

  Werner, Haim ^a   Roith, Derek Le ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Cell cycle; Oncogene; p53; Signal transduction; Transcription; Tumor suppressors; Tyrosine kinase; WT1

Indexed keywords

PROTEIN P53; PROTEIN TYROSINE KINASE; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR;

APOPTOSIS; BREAST CANCER; CARCINOGENESIS; CELL CYCLE; GENE EXPRESSION; KNOCKOUT MOUSE; NONHUMAN; ONTOGENY; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 0344734066     PISSN: 08939675     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevOncog.v8.i1.40     Document Type: Review

References (183)

1. Abbott, A. M., R. Bueno, M. T. Pedrini, J. M. Murray, and R. J. Smith: Insulin-like growth factor I receptor gene structure. J. Biol. Chem., 267:10759-10763 (1992).
2. Almeida, A., M. Muleris, B. Dutrillaux, and B. Malfoy: The insulin-like growth factor I receptor gene is the target for the 15q26 amplicon in breast cancer. Genes, Chromosomes Cancer, 11:63-65 (1994).
3. Ambrose, D., M. Resnicoff, D. Coppola, C. Sell, M. Miura, S. Jameson, R. Baserga, and R. Rubin: Growth regulation of human glioblastoma T98G cells by insulinlike growth factor I (IGF-I) and the IGF-I receptor. J. Cell. Physiol., 159:92-100 (1994).
4. Arteaga, C. L., L. J. Kitten, E. B. Coronado, S. Jacobs, F. C. Kull, Jr, D. C. Allred, and C. K. Osborne: Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J. Clin. Invest., 84:1418-1423 (1989).
5. Arteaga, C. L. and C. K. Osborne: Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res., 49:6237-6241 (1989).
6. Baker, J., J.-P. Liu, E. J. Robertson, and A. Efstratiadis: Role of insulin-like growth factors in embryonic and postnatal growth. Cell, 75:73-82 (1993).
7. Baserga, R.: The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res., 55:249-252 (1995).
8. Baserga, R.: Oncogenes and the strategy of growth factors. Cell, 79:927-930 (1994).
9. Baserga, R. and R. Rubin: Cell cycle and growth control. Crit. Rev. Euk. Gene Exp., 3:47-61 (1993).
10. Baserga, R., C. Sell, P. Porcu, and M. Rubini: The role of the IGF-I receptor in the growth and transformation of mammalian cells. Cell Proliferation, 27:63-71 (1994).
11. Bassas, L., F. DePablo, M. A. Lesniak, and J. Roth: Ontogeny of receptors for insulin-like peptides in chick embryo tissues: early dominance of insulin-like growth factor over insulin receptors in brain. Endocrinology, 117:2321-2329 (1985).
12. Bassas, L., M. Girbau, M. A. Lesniak, J. Roth, and F. DePablo: Development of receptors for insulin-like growth factor-I in head and brain of chick embryos: autoradiographic localization. Endocrinology, 125:2320-2326 (1989).
13. Biegel, J. A., K. Conard and J. J. Brooks: Translocation (11;22) (p13;q12): Primary changes in intra-abdominal desmoplastic small round cell tumor. Genes Chromosomes Cancer, 7:119-121 (1993).
14. Blakesley, V. A., T. Kalebic, L. J. Helman, B. Stannard, T. N. Faria, C. T. Roberts, Jr., and D. LeRoith: Tumorigenic and mitogenic capacites are reduced in transfected fibroblats expressing mutant insulin-like growth factor (IGF)-I receptors. The role of tyrosine residues 1250, 1251, and 1316 in the carboxy-terminus of the IGF-I receptor. Endocrinology, 137:410-417 (1996).
15. Bondy, C. A., H. Werner, C. T. Roberts, Jr., and D. LeRoith: Cellular pattern of insulin-like growth factor I (IGFI) and type I IGF receptor gene expression in early organogenesis: comparison with IGF-II gene expression. Mol. Endocrinol., 4:1386-1398 (1990).
16. Bondy, C. A., H. Werner, C. T. Roberts, Jr., and D. LeRoith: Cellular pattern of Type I insulin-like growth factor receptor gene expression during maturation of the rat brain: comparison with insulin-like growth factors I and II. Neuroscience, 46:909-923 (1992).
17. Buckbinder, L., R. Talbott, S. Velasco-Miguel, I. Takenaka, B. Faha, B. R. Seizinger, and N. Kley: Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature, 377:1367-1373 (1995).
18. Call, K. M., T. Glaser, C. Y. Ito, A. J. Buckler, J. Pelletier, D. A. Haber, E. A. Rose, A. Kral, H. Yeger, W. H. Lewis, C. Jones, and D. E. Housman: Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell, 60:509-520 (1990).
19. Clemmons, D. R.: Multiple hormones stimulate the production of somatomedin by cultured human fibroblasts. J. Clin. Endocrinol. Metab., 58:850-859 (1984).
20. Clemmons, D. R. and D. S. Shaw: Variables controlling somatomedin production by cultured human fibroblasts. J. Cell. Physiol, 115:139-142 (1983).
21. Cohick, W. S. and D. R. Clemmons: The insulin-like growth factors. Ann. Rev. Physiol, 55:131-153 (1993).
22. Cooke, D. W., L. A. Bankert, C. T. Roberts, Jr., D. LeRoith, and S. J. Casella: Analysis of the human type I insulinlike growth factor receptor promoter region. Biochem. Biophys. Res. Comm., 177:1113-1120 (1991).
23. Cooke, D. W. and S. J. Casella: The 5′-untranslated region of the IGF-I receptor gene modulates reporter gene expression by both pre- and posttranscriptional mechanisms. Mol. Cell. Endocrinol., 101:77-84 (1994).
24. Coppes, M. J., D. A. Haber, and P. E. Grundy: Genetic events in the development of Wilms' tumor. New Engl. J. Med., 331:586-590 (1994).
25. Courey, A. J. and R. Tjian: Mechanisms of transcriptional control as revealed by studies of human transcription factor Spl. In: Transcriptional Regulation (McKnight, S. and K. Yamamoto, Eds.) Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 743-769 (1992).
26. Craparo, A., R. Freund, and T. A. Gustafson: 14-3-3 interacts with the insulin-like growth factor-I receptor and insulin receptor substrate-I in a phosphoserine-dependent manner. J. Biol. Chem., 272:11663-11669 (1997).
27. Cullen, K. I., D. Yee, W. S. Sly, J. Perdue, B. Hampton, M. E. Lippman, and N. Rosen: Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res., 50:48-53 (1990).
28. D'Mello, S. R., C. Galli, T. Ciotti, and P. Calissano: Induction of apoptosis in cerebellar granule neurons by low potassium: inhibition of death by insulin-like growth factor-I and cAMP. Proc. Natl. Acad. Sci. U.S.A., 90:10989-10993 (1993).
29. Daughaday, W. and P. Rotwein: Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr. Rev., 10:68-91 (1989).
30. Datta, S. R., H. Dudek, X. Tao, S. Masters, H. Fu, Y. Gotoh, and M. Greenberg: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell, 91:231-241 (1997).
31. DeChiara, T. M., A. Efstratiadis, and E. J. Robertson: A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature, 345:78-80 (1990).
32. deKlein, A., A. G. van Kessel, G. Grosveld, C. R. Bartram, A. Hagemeijer, D. Bootsma, N. K. Spurr, N. Heiterkamp, and J. Groffen: A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia. Nature, 300:765-767 (1982).
33. Dey, B. R., V. P. Sukhatme, A. B. Roberts, M. B. Sporn, F. J. Rauscher, III and S.-J. Kim: Repression of the transforming growth factor-βl gene by the Wilms' tumor suppressor WT1 gene product. Mol. Endocrinol., 8:595-602 (1994).
34. Drummond, I. A., S. L. Madden, P. Rohwer-Nutter, G. I. Bell, V. P. Sukhatme, and F. J. Rauscher, III: Repression of the insulin-like growth factor II gene by the Wilms' tumor suppressor WT1. Science, 257:674-678 (1992).
35. Dudek, H., S. R. Datta, T. F. Franke, M. J. Birnbaum, R. Yao, G. M. Cooper, R. S. Segal, D. R. Kaplan, and M. E. Greenberg: Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science, 275:661-665 (1997).
36. El-Badry, O. M., J. A. Romanus, L. J. Helman, M. J. Cooper, M. M. Rechler, and M. A. Israel: Autonomous growth of a human neuroblastoma cell line is mediated by insulin-like growth factor II. J. Clin. Invest., 84:829-839 (1989).
37. El-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinsler, and B. Vogelstein: WAF1, a potential mediator of p53 tumor suppression. Cell, 75:817-825 (1993).
38. Fisher, D. E.: Apoptosis in cancer therapy: crossing the threshold. Cell, 78:539-542 (1994).
39. Furlanetto, R. W., S. E. Harwell, and R. B. Baggs: Effects of insulin-like growth factor receptor inhibition on human melanomas in culture and in athymic mice. Cancer Res., 53:2522-2526 (1993).
40. Furlanetto, R. W., S. E. Harwell, and K. K. Frick: Insulinlike growth factor-I induces cyclin-D1 expression in MG63 human osteosarcoma cells in vitro. Mol. Endocrinol., 8:510-517 (1994).
41. Gansler, T., R. Furlanetto, T. S. Gramling, K. A. Robinson, N. Blocker, M. G. Buse, D. A. Sens, and A. J. Garvin: Antibody to Type I insulin-like growth factor receptor inhibits growth of Wilms' tumor in culture and in athymic mice. Am. J. Pathol, 135:961-966 (1989).
42. Gashler, A. L., D. T. Bonthron, S. L. Madden, F. J. Rauscher, III, T. Collins, and V. P. Sukhatme: Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms' tumor suppressor WT1. Proc. Natl. Acad. Sci. U.S.A., 89:10984-10988 (1992).
43. Gerald, W. L., J. Rosai, and M. Ladanyi: Characterization of the genomic breakpoint and chimeric transcripts in the EWS-WT1 gene fusion of desmoplastic small round cell tumor. Proc. Natl. Acad. Sci. U.S.A., 92:1028-1032(1995).
44. Gessler, M., A. Poustka, W. Cavence, R. L. Neve, S. H. Orkin, and G. A. P. Bruns: Homozygous deletion in Wilms' tumors of a zinc-finger gene identified by chromosome jumping. Nature, 343:774-778 (1990).
45. Goldfine, I. D., V. Papa, R. Vigneri, P. Siiteri, and S. M. Rosenthal: Progestin regulation of insulin and insulinlike growth factor I receptors in cultured human breast cancer cells. Mol. Endocrinol., 6:1665-1672 (1992).
46. Haber, D. A., S. Park, S. Maheswaran, C. Englert, G. G. Re, D. J. Hazen-Martin, D. A. Sens, and A. J. Garvin: WT1-mediated growth suppression of Wilms' tumor cells expressing a WT1 splicing variant. Science, 262:2057-2059 (1993).
47. Harrington, E. A., M. R. Bennett, A. Fanidi, and G. I. Evan: c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J., 13:3286-3295 (1994).
48. Harrington, M. A., B. Konicek, A. Song, Z.-I. Zia, S. J. Fredericks, and F. J. Rauscher, III: Inhibition of colony-stimulating factor I promoter activity by the product of theWilms' tumor locus. J. Biol. Chem., 268:21271-21276 (1993).
49. Harris, C. C. and M. Hollstein: Clinical implications of the p53 tumor suppressor gene. N. Engl. J. Med., 329:1318-1327(1993).
50. Hartwell, L. H. and M. B. Kastan: Cell cycle control and cancer. Science, 266:1821-1828 (1994).
51. Hartwell, L. H. and T. A. Weinert: Check points: controls that ensure the order of cell cycle events. Science, 246:629-634 (1989).
52. Hastie, N. D.: The genetics of Wilms' tumor - A case of disrupted development. Ann. Rev. Genet., 28:523-558 (1994).
53. Hernandez-Sanchez, C., H. Werner, C. T. Roberts, Jr., E. J. Woo, D. W. Hun, S. M. Rosenthal, and D. LeRoith: Differential regulation of IGF-I receptor gene expression by IGF-I and basic fibroblast growth factor. J. Biol. Chem., 272:4663-4670 (1997).
54. Hollstein, M., D. Sidransky, B. Vogelstein, and C. C. Harris: p53 mutations in human cancers. Science, 253:49-53 (1991).
55. Jacobs, S. and P. Cuatrecasas: Phosphorylation of receptors for insulin and insulin-like growth factor I. J. Biol. Chem., 261:934-939 (1986).
56. Jacobs, S., F. C. Kull, Jr., and P. Cuatrecasas: Monensin blocks the maturation of receptors for insulin and somatomedin C: identification of receptor precursors. Proc. Natl. Acad. Sci. U.S.A., 80:1228-1232 (1983).
57. Jammes, H., J. P. Peyrat, E. Ban, M. O. Vilain, F. Haour, J. Djiane, and J. Bonneterre: Insulin-like growth factor I receptors in human breast tumour: localization and quantification by histo-autoradiographic analysis. Br. J. Cancer, 66:248-253 (1992).
58. Kato, H., T. N. Faria, B. Stannard, C. T. Roberts, Jr., and D. Le Roith: Role of tyrosine kinase activity in signal transduction by the IGF-I receptor. J. Biol. Chem., 268:2655-2661 (1993).
59. Kageyama, R., G. T. Merlino, and I. Pastan: Nuclear factor ETF specifically stimulates transcription from promoters without a TATA box. J. Biol. Chem., 264:15508-15514(1989).
60. Kaleko, M., W. J. Rutter, and A. D. Miller: Overexpression of the human insulin-like growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol. Cell. Biol., 10:464-473 (1990).
61. Kappel, C. C., M. C. Velez-Yanguas, S. Hirschfeld, and L. J. Helman: Human osteosarcoma cells are dependent on insulin-like growth factor I for in vitro growth. Cancer Res., 54:2803-2807 (1994).
62. Kapur, S., H. Tamada, S. K. Dey, and G. K. Andrews: Expression of insulin-like growth factor-I (IGF-I) and its receptor in the peri-implantation mouse uterus, and cell-specific regulation of IGF-I gene expression by estradiol and progesterone. Biol. Reprod., 46:208-219(1992).
63. Karnieli, E., H. Werner, F. J. Rauscher, III, L. E. Benjamin, and D. LeRoith: The IGF-I receptor gene promoter is a molecular target for the Ewings' sarcoma-Wilms' tumor 1 fusion protein. J. Biol. Chem., 271:19304-19309 (1996).
64. Kastan, M. B., Q. Zhan, W. El-Deiry, F. Carrier, T. Jacks, W. V. Walsh, B. S. Plunkett, and A. J. Fornace, Jr.: A mammalian cell cycle check point pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 71:587-597 (1992).
65. Kato, H., T. N. Faria, B. Stannard, C. T. Roberts, Jr., and D. LeRoith: Essential role of tyrosine residues 1131, 1135, and 1136 of the insulin-like growth factor-I (IGF-I) receptor in IGF-I action. Mol. Endocrinol., 8:40-50 (1994).
66. Kato, H., T. N. Faria, B. Stannard, C. T. Roberts, Jr., and D. LeRoith: Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGFI) receptor. J. Biol. Chem., 268:2655-2661 (1993).
67. Kaye, P. L., K. L. Bell, L. F. Beebe, G. F. Dunglison, H. G. Gardner and M. B. Harvey: Insulin and the insulinlike growth factors (IGFs) in preimplantation development. Reprod. Fertil. Dev., 4:373-386 (1992).
68. Kern, S. E., K. W. Kinzler, A. Bruskin, D. Jarosz, P. Friedman, C. Prives, and B. Vogelstein: Identification of p53 as a sequence-specific DNA-binding protein. Science, 252:1708-1711 (1991).
69. Kim, S. O., J. G. Park, and Y. I. Lee: Increased expression of the insulin-like growth factor I (IGF-I) receptor gene in hepatocellular carcinoma cell lines: implications of IGFI receptor gene activation by hepatitis B virus X gene product. Cancer Res., 56:3831-3836 (1996).
70. Kjeldsen, T., A. S. Andersen, F. C. Wiberg, J. S. Rasmussen, L. Schaffer, P. Balschmidt, K. B. Moller, and N. P. H. Moller: The ligand specificities of the insulin receptor and the insulin-like growth factor I receptor reside in different regions of a common binding site. Proc. Natl. Acad. Sci. U.S.A., 88:4404-4408 (1991).
71. Knudson, A. G.: Antioncogenes and human cancer. Proc. Natl. Acad. Sci. U.S.A., 90:10914-10921 (1993).
72. Kozma, L. M. and M. J. Weber: Constitutive phosphorylation of the receptor for insulin like growth factor I in cells transformed by the src oncogene. Mol. Cell. Biol., 10:3626-3634 (1990).
73. Kraft, A., L. M. Reid. and I. Zvibel: Suramin inhibits growth and yet promotes insulin-like growth factor II expression in HepG2 cells. Cancer Res., 53:652-657 (1993).
74. Kreidberg, J., H. Sariola, J. M. Loring, M. Maeda, J. Pelletier, D. Housman, and R. Jaenisch: WT1 is required for early kidney development. Cell, 74:679-691 (1993).
75. Ladanyi, M. and W. Gerald: Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor. Cancer Res., 54:2837-2840 (1994).
76. Lahm, H., P. Amstad, J. Wyniger, A. Yilmaz, J. R. Fisher, M. Schreyer, and J. C. Givel: Blockade of the insulinlike growth factor I receptor inhibits growth of human colorectal cancer cells: evidence of a functional IGF-II mediated autocrine loop. Int. J. Cancer, 58:452-459 (1994).
77. LeRoith, D., M. Adamo, H. Werner, and C. T. Roberts, Jr.: Insulin-like growth factors and their receptors as growth regulators in normal physiology and pathological states. Trends Endocrinol. Metab., 2:134-139 (1991).
78. LeRoith, D., H. Werner, D. Beitner-Johnson, and C. T. Roberts, Jr.: Molecular and cellular aspects of the insulinlike growth factor I receptor. Endocr. Rev., 16:143-163 (1995).
79. Li, S. and R. Baserga: Epidermal growth factor and plateletderived growth factor regulate the activity of the insulin-like growth factor I gene promoter. Exp. Gerontol., 31:195-206(1996).
80. Little, M. H., J. Prosser, A. Condie, P. J. Smith, V. Van Heyningen, and N. D. Hastie: Zinc finger point mutations within the WT1 gene in Wilms' tumor patients. Proc. Natl. Acad. Sci. U.S.A., 89:4791-4795 (1992).
81. Liu, J.-L., V. A. Blakesley, J. S. Gutkind, and D. LeRoith: The constitutively active mutant Ga13 transforms mouse fibroblast cells deficient in insulin-like growth factor-I receptor. J. Biol. Chem., 272:29438-29441 (1997).
82. Liu, J.-P., J. Baker, A. S. Perkins, E. J. Robertson, and A. Estratiadis: Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell, 75:59-72 (1993).
83. Lowe, W. L., Jr.: Biological actions of the insulin-like growth factors. In: Insulin-Like Growth Factors: Molecular and Cellular Aspects (LeRoith, D., Ed.) CRC Press, Boca Raton, EL, 49-85 (1991).
84. Lowe, W. L., Jr., M. Adamo, H. Werner, C. T. Roberts, Jr., and D. LeRoith: Regulation by fasting of rat insulin-like growth factor I and its receptor. Effects on gene expression and binding. J. Clin. Invest., 84:619-626 (1989).
85. Macaulay, V. M.: Insulin-like growth factors and cancer. Br. J. Cancer, 65:311-320 (1992).
86. Macaulay, V. M., M. J. Everard, J. D. Teale, P. A. Trott, J. J. Van Wyk, I. E. Smith, and J. L. Millar: Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells. Cancer Res., 50:2511-2517 (1990).
87. Madden, S. L., D. M. Cook, J. F. Morris, A. Gashler, V. P. Sukhatme, and F. J. Rauscher, III: Transcriptional repression mediated by the WT1 Wilms' tumor gene product. Science, 253:1550-1553 (1991).
88. Mamula, P. W. and I. D. Goldfine: Cloning and characterization of the human insulin-like growth factor-I receptor gene 5′-flanking region. DNA Cell Biol., 11:43-50 (1992).
89. Marshall, C. J.: Tumor suppressor genes. Cell, 64:313-326 (1991).
90. McCubrey, J. A., L. S. Steelman, M. W. Mayo, P. A. Algate, R. A. Dellow, and M. Kaleko: Growth-promoting effects of insulin-like growth factor-I (IGF-I) on hematopoietic cells: overexpression of introduced IGFI receptor abrogates interleukin-3 dependency of murine factor-dependent cells by a ligand -dependent mechanism. Blood, 78:921-929 (1991).
91. Mercer, W. E.: Cell cycle regulation and the p53 tumor suppressor protein. Crit. Rev. Euk. Gene Exp., 2:251-263 (1992).
92. Minniti, C. P., M. Maggi, and L. J. Helman: Suramin inhibits the growth of human rhabdomyosarcoma by interrupting the insulin-like growth factor II autocrine growth loop. Cancer Res., 52:1830-1835 (1992).
93. Minuto, F., P. Del Monte, A. Barreca, A. Alama, G. Cariola, and G. Giordano: Evidence for autocrine mitogenic stimulation by somatomedin-C insulin-like growth factor I on an established human lung cancer cell line. Cancer Res., 48:3716-3723 (1988).
94. Morrione, A., T. DeAngelis, and R. Baserga: Failure of the bovine papillomavirus to transform mouse embryo fibroblasts with a targeted disruption of the insulinlike growth factor I receptor gene. J. Virol., 69:5300-5303 (1995).
95. Morrione, A., T. DeAngelis, and R. Baserga: The GC factor regulates the expression of the insulin-like growth factor-I receptor. Cell Proliferation, 28:659-671 (1995).
96. Morris, G. F., J. R. Bischoff, and M. B. Mathews: Transcriptional activation of the human proliferating-cell nuclear antigen promoter by p53. Proc. Natl. Acad. Sci. U.S.A., 93:895-899 (1996).
97. Morris, J. F., S. L. Madden, O. E. Tournay, D. M. Cook, V. P. Sukhatme, and F. J. Rauscher, III: Characterization of the zinc finger protein encoded by the WT1 Wilms' tumor locus. Oncogene, 6:2339-2348 (1991).
98. Muta, K. and S. B. Krantz: Apoptosis of human erythroid colony-forming cells is decreased by stem cell factor and insulin-like growth factor-I as well as erythropoietin. J. Cell. Physiol, 156:264-271 (1993).
99. Neuenschwander, S., C. T. Roberts, Jr., and D. Le Roith: Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor-I receptor antisense ribonucleic acid. Endocrinology, 136:4298-4303 (1995).
100. Nissley, S. P. and W. Lopaczynski: Insulin-like growth factor receptors. Growth Factors, 5:29-49 (1991).
101. O'Connor, R., A. Kauffmann-Zeh, Y. Liu, S. Lehar, G. I. Evan, R. Baserga, and W. A. Blattler: Identification of domains of the insulin-like growth factor I receptor that are required for protection from apoptosis. Mol. Cell. Biol., 17:427-435 (1997).
102. Oren, M.: p53: The ultimate tumor suppressor gene? FASEB J., 6:3169-3176(1992).
103. Osborne, C. K., E. B. Coronado, L. J. Kitten, C. I. Arteaga, S. A. W. Fuqua, K. Ramasharma, M. Marshall, and C. H. Li: Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. Mol. Endocrinol, 3:1701-1709(1989).
104. Ota, A., Z. Shen-Orr, C. T. Roberts, Jr., and D. LeRoith: TPA-induced neurite formation in a neuroblastoma cell line (SH-SY5Y) is associated with increased IGF-I receptor mRNA and binding. Mol. Brain Res., 6:69-76(1989).
105. Ozbun, M. A. and J. S. Butel: Tumor suppressor p53 mutations and breast cancer: a critical analysis. Adv. Cancer Res., 66:71-141 (1995).
106. Papa, V., K. K. P. Hartmann, S. M. Rosenthal, B. A. Maddux, P. K. Siiteri, and I. D. Goldfine: Progestins induce down-regulation of insulin-like growth factor (IGF-I) receptors in human breast cancer cells; potential autocrine role of IGF-II. Mol. Endocrinol., 5:709-717 (1991).
107. Pardee, A. B.: G1 events and regulation of cell proliferation. Science, 246:603-608 (1989).
108. Parrizas, M. and D. LeRoith: Insulin-like growth factor I inhibition of apoptosis is associated with increased expression of the bcl-xL gene product. Endocrinology, 138:1355-1358 (1997).
109. Peoples, R., A. Milatovich, and U. Francke: Hemizygosity at the insulin-like growth factor I receptor (IGF1R) locus and growth failure in the ring chromosome 15 syndrome. Cytogenet. Cell Genetics, 70:228-234 (1995).
110. Peterson, J. E., T. Jelinek, M. Kaleko, K. Siddle, and M. J. Weber: C phosphorylation and activation of the IGFI receptor in src-transformed cells. J. Biol. Chem., 269:27315-27321 (1994).
111. Peyrat, J.-P., J. Bonneterre, R. Beuscart, J. Dijane, and A. Demaille: Insulin-like growth factor I receptors in human breast cancer and their relation to estradiol and progesterone receptors. Cancer Res., 48:6429-6436(1988).
112. Pietenpol, J. A., T. Tokino, S. Thiagalingam, W. S. El-Deiry, K. W. Kinzler, and B. Vogelstein: Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc. Natl. Acad. Sci. U.S.A., 91:1998-2002(1994).
113. Pietrzkowski, Z., R. Lammers, G. Carpenter, A. M. Soderquist, M. Limardo, P. D. Phillips, A. Ullrich, and R. Baserga: Constitutive expression of insulinlike growth factor I and insulin-like growth factor I receptor abrogates all requirements for exogenous growth factors. Cell Growth Differ., 3:199-205 (1992).
114. Pietrzkowski, Z., G. Mulholland, L. Gomella, B. A. Jameson, D. Wernicke, and R. Baserga: Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor I. Cancer Res., 53:1102-1106(1993).
115. Pietrzkowski, Z., C. Sell, R. Lammers, A. Ullrich, and R. Baserga: Roles of insulin-like growth factor I (IGFI) and the IGF-I receptor in epidermal growth factor-stimulated growth of 3T3 cells. Mol. Cell. Biol., 12 (1992).
116. Prager, D., H.-L. Li, S. Asa, and S. Melmed: Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant. Proc. Natl. Acad. Sci. U.S.A., 91:2181-2185 (1994).
117. Prior, T. I., L. J. Helman, D. J. FitzGerald, and I. Pastan: Cytotoxic activity of a recombinant fusion protein between insulin-like growth factor I and Pseudomonas exotoxin. Cancer Res., 51:174-180 (1991).
118. Prisco, M., A. Hongo, M. G. Rizzo, A. Sacchi, and R. Baserga: The insulin-like growth factor I receptor as a physiologically relevant target of p53 in apoptosis caused by interleukin-3 withdrawal. Mol. Cell. Biol., 17:1084-1092(1997).
119. Rabbitts, T. H.: Chromosomal translocations in human cancer. Nature, 372:143-149 (1994).
120. Raile, K., A. Hoflich, U. Kessler, Y. Yang, M. Pfuender, W. F. Blum, H. Kolb, H. P. Schwarz, and W. Kiess: Human osteosarcoma (U-2 OS) cells express both insulin-like growth factor-I (IGF-I) receptors and insulin-like growth factor II/mannose-6-phosphate (IGFII/M6P) receptors and synthesize IGF-II: autocrine growth stimulation by IGF-II via the IGF-I receptor. J. Cell. Physiol., 159:531-541 (1994).
121. Rappolee, D. A. and Z. Werb: Endogenous insulin-like growth factor II mediates growth in preimplantation mouse embryos. In: Modern Concepts of InsulinLike Growth Factors (Spencer, E. M., Ed.) Elsevier, New York, 3-8 (1991).
122. Rauscher, F. J., III: The WT1 Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor. FASEB J., 7:896-903 (1993).
123. Rauscher, F. J., III, L. E. Benjamin, W. J. Fredericks, and J. F. Morris: Novel oncogenic mutations in the WT1 Wilms' tumor suppressor gene: A t(11;22) fuses the Ewings ' sarcoma gene, EWS1, to WT1 in desmoplastic small round cell tumor. Cold Spring Harbor Symposia Quantitative Biology, 59:137-146 (1994).
124. Rauscher, F. J., III, J. F. Morris, O. E. Tournay, D. M. Cook, and T. Curran: Binding of the Wilms' tumor locus zinc finger protein to the EGR-1 consensus sequence. Science, 250:1259-1262 (1990).
125. Rechler, M. M.: Insulin-like growth factor binding proteins. Vitam. Horm., 47:1-114 (1993).
126. Reiss, K., A. Ferber, S. Travali, P. Porcu, P. D. Phillips, and R. Baserga: The protooncogene c-myb increases the expression of insulin-like growth factor I and insulin-like growth factor I receptor messenger RNAs by a transcriptional mechanism. Cancer Res., 51:5997-6000 (1991).
127. Reiss, K., P. Porcu, C. Sell, Z. Pietrzkowski, and R. Baserga: The insulin-like growth factor I receptor is required for the proliferation of hemopoietic cells. Oncogene, 7:2243-2248 (1992).
128. Resnicoff, M., D. Abraham, W. Yutanawiboonchai, H. L. Rotman, J. Kajstura, R. Rubin, P. Zoltick, and R. Baserga: The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res., 55:2463-2469 (1995).
129. Resnicoff, M., J.-L. Burgaud, H. L. Rotman, D. Abraham, and R. Baserga: Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor I receptors. Cancer Res., 55:3739-3741 (1995).
130. Resnicoff, M., D. Coppola, C. Sell, R. Rubin, S. Ferrone, and R. Baserga: Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res., 54:4848-4850 (1994).
131. Resnicoff, M., W. Li, S. Basak, D. Herlyn, R. Baserga, and R. Rubin: Inhibition of rat C6 glioblastoma tumor growth by expression of insulin-like growth factor I receptor antisense mRNA. Cancer Immunology Immunotherapy, 42:64-68 (1996).
132. Resnicoff, M., C. Sell, M. Rubini, D. Coppola, D. Ambrose, R. Baserga. and R. Rubin: Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor I (IGF-I) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res., 54:2218-2222 (1994).
133. Roback, E. W., A. J. Barakat, V. G. Dev, M. Mbikay, M. Chreitien, and M. G. Butler: An infant with deletion of the distal long arm of chromosome 15 (q26.1 →qter) and loss of insulin-like growth factor I receptor gene. Am. J. Med. Genet., 38:74-79 (1991).
134. Rodriguez-Tarduchy, G., M. K. L. Collins, I. Garcia, and A. Lopez-Rivas: Insulin-like growth factor-I inhibits apoptosis in IL-3-dependent hemopoietic cells. J. Immunol, 149:535-540 (1992).
135. Roesler, W. J., G. R. Vandenbark, and R. W. Hanson: Cyclic AMP and the induction of eukaryotic gene transcription. J. Biol. Chem., 263:9063-9066 (1988).
136. Rose, E. A., T. Glaser, C. Jones, C. L. Smith, W. H. Lewis, K. M. Call, M. Minden, E. Champagne, L. Bonetta, H. Yeger, and D. E. Housman: Complete physical map of the WAGR region of 11 p13 localizes a candidate Wilms' tumor gene. Cell, 60:495-508 (1990).
137. Rosenthal, S. M. and Z.-Q. Cheng: Opposing early and late effects of insulin-like growth factor I on differentiation and the cell cycle regulatory retinoblastoma protein in skeletal myoblasts. Proc. Natl. Acad. Sci. U.S.A., 92:10307-10311 (1995).
138. Rubin, R. and R. Baserga: Insulin-like growth factor-I receptor. Lab. Invest., 73:311-331 (1995).
139. Rubini, M., A. Hongo, C. D'Ambrosio, and R. Baserga: The IGF-I receptor in mitogenesis and transformation of mouse embryo cells: role of receptor number. Exp. Cell Res., 230:284-292 (1997).
140. Rubini, M., H. Werner, E. Gandini, C. T. Roberts, Jr., D. LeRoith, and R. Baserga: Platelet-derived growth factor increases the activity of the promoter of the IGF-I receptor gene. Exp. Cell Res., 211:374-379 (1994).
141. Rukenstein, A., R. E. Rydel, and L. A. Greene: Multiple agents rescue PC 12 cells from serum-free cell death by translation- and transcription-independent mechanisms. J. Neurosci., 11:2552-2563 (1991).
142. Russell, W. E., J. J. Van Wyk, and W. J. Pledger: Inhibition of the mitogenic effect of plasma by a monoclonal antibody to somatomedin C. Proc. Natl. Acad. Sci. U.S.A., 81:2389-2393 (1984).
143. Sawyer, J. R., A. F. Tryka, and J. M. Lewis: A novel reciprocal chromosome translocation t(11;22)(p13;q12) in an intraabdominal desmoplastic small round cell tumor. Am. J. Surg. Pathol, 16:411-416 (1992).
144. Scavo, L., A. R. Shuldiner, J. Serrano, R. Dashner, J. Roth, and F. dePablo: Genes encoding receptors for insulin and insulin-like growth factor I are expressed in Xenopus oocytes and embryos. Proc. Natl. Acad. Sci. U.S.A., 88:6214-6218 (1991).
145. Schultz, G. A., A. Hahnel, M. Arcellana-Panlilio, L. Wang, S. Goubau, A. Watson, and M. Harvey: Expression of IGF ligand and receptor genes during preimplantation mammalian development. Mol. Reprod. Dev., 35:414-420 (1993).
146. Seino, S., M. Seino, and G. I. Bell: Human insulin receptor gene. Diabetes, 39:129-133 (1990).
147. Seino, S., M. Seino, S. Nishi, and G. I. Bell: Structure of the human insulin receptor gene and characterization of its promoter. Proc. Natl. Acad. Sci. U.S.A., 86:114-118(1989).
148. Selivanova, G. and K. G. Wiman: p53: A cell cycle regulator activated by DNA damage. Adv. Cancer Res., 66:143-180 (1995).
149. Sell, C., R. Baserga, and R. Rubin: Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis. Cancer Res., 55:303-306(1995).
150. Sell, C., G. Dumenil, C. Deveaud, M. Miura, D. Coppola, T. DeAngelis, R. Rubin, A. Efstratiadis, and R. Baserga: Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol. Cell. Biol., 14:3604-3612 (1994).
151. Sell, C., M. Rubini, R. Rubin, J.-P. Liu, A. Efstratiadis, and R. Baserga: Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc. Natl. Acad. Sci. U.S.A., 90:11217-11221 (1993).
152. Shapiro, D., B. G. Jones, L. H. Shapiro, P. Dias, and P. J. Houghton: Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma. J. Clin. Invest., 94:1235-1242 (1994).
153. Shemer, J., M. Adamo, M. K. Raizada, D. Heffez, Y. Zick, and D. LeRoith: Insulin and IGF-I stimulate phosphorylation of their respective receptors in intact neuronal and glial cells in primary culture. J. Mol. Neurosci., 1:3-8 (1989).
154. Shen, W. P., B. Towne, and T. M. Zadeh: Cytogenetic abnormalities in an intra-abdominal desmoplastic small cell tumor. Cancer Genetics Cytogenetics, 64:189-191 (1992).
155. Siebler, T., W. Lopazynski, C. L. Terry, S. J. Casella, P. Munson, D. De Leon, L. Phang, K. J. Blakemore, R. C. McEvoy, R. I. Kelley, and P. Nissley: Insulin-like growth factor I receptor expression and function in fibroblasts from two patients with deletion of the distal long arm of chromosome 15. J. Clin. Endocrinol. Metab., 80:3447-3457 (1995).
156. Singelton, J. R., V. M. Dixit, and E. L. Feldman: Type-I insulin-like growth factor receptor activation regulates apoptotic proteins. J. Biol. Chem., 271:31791-31794(1996).
157. Smale, S. T. and D. Baltimore: The "initiator" as a transcription control element. Cell, 57:103-113 (1989).
158. Steller, M. A., Z. Zou, J. T. Schiller, and R. Baserga: Transformation by human papillomavirus 16 E6 and E7: Role of the insulin-like growth factor 1 receptor. Cancer Res., 56:5087-5091 (1996).
159. Stewart, A. J., M. D. Johnson, F. E. B. May, and B. R. Westley: Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen stimulated proliferation of human breast cancer cells. J. Biol. Chem., 265:21172-21178 (1990).
160. Stiles, C. D., G. T. Capone, C. D. Scher, N. H. Antoniades, J. J. Van Wyk, and W. J. Pledger: Dual control of cell growth by somatomedins and platelet derived growth factor. Proc. Natl. Acad. Sci. U.S.A., 76:1279-1283 (1979).
161. Sukhatme, V. P.: The EGR transcription factor family: from signal transduction to kidney differentiation. Kidney Int., 41:550-553 (1992).
162. Sundaresan, S. and U. Francke: Insulin-like growth factor I receptor gene is concordant with c-fes protooncogene and mouse chromosome 7 in somatic cell hybrids. Som. Cell Mol. Gen., 15:373-378 (1989).
163. Travail, S., K. Reiss, A. Ferber, S. Petralia, W. E. Mercer, B. Calabreta, and R. Baserga: Constitutively expressed c-myb abrogates the requirement for insulinlike growth factor I in 3T3 fibroblasts. Mol. Cell. Biol., 11:731-736 (1991).
164. Ullrich, A., J. R. Bell, E. Y. Chen, R. Herrera, L. M. Petruzzeli, T. J. Dull, A. Gray, L. Coussens, Y.-C. Liao, M. Tsubokawa, A. Mason, P. H. Seeburg, C. Grunfeld, O. M. Rosen, and J. Ramachandran: Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature, 313:756-761
165. Ullrich, A., A. Gray, A. W. Tam, T. Yang-Feng, M. Tsubowka, C. Collins, W. Henzel, T. Lebon, S. Kathuria, F. Chen, S. Jacobs, U. Francke, J. Ramachandran, and Y. FujitaYamaguchi: Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests determinants that define functional specificity. EMBO J., 5:2503-2512 (1986).
166. Wada, J., Z. Z. Liu, K. Alvares, A. Kumar, E. Wallner, H. Makino and Y. S. Kanwar: Cloning of cDNA for the alpha subunit of the mouse insulin-like growth factor I receptor and the role of the receptor in metanephric development. Proc. Natl. Acad. Sci. U.S.A., 90:10360-10364 (1993).
167. Weinberg, R.: Tumor suppressor genes. Neuron, 11:191-196 (1993).
168. Werner, H., M. Adamo, C. T. Roberts, Jr., and D. LeRoith: Molecular and cellular aspects of insulin-like growth factor action. In: Vitamins and Hormones (Litwack, G., Ed.) Academic Press, San Diego, CA, 1-58 (1994).
169. Werner, H., M. A. Bach, B. Stannard, C. T. Roberts, Jr., and D. LeRoith: Structural and functional analysis of the insulin-like growth factor I receptor gene promoter. Mol. Endocrinol., 6:1545-1558 (1992).
170. Werner, H., E. Karnieli, F. J. Rauscher, III, and D. LeRoith: Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc. Natl. Acad. Sci. U.S.A., 93:8318-8323 (1996).
171. Werner, H. and D. LeRoith: Insulin-like growth factor I receptor: structure, signal transduction, and function. Diabetes Reviews, 3:28-37 (1995).
172. Werner, H. and D. LeRoith: The role of the insulin-like growth factor system in human cancer. Adv. Cancer Res., 68:183-223 (1996).
173. Werner, H., F. J. Rauscher, III, V. P. Sukhatme, I. A. Drummond, C. T. Roberts, Jr., and D. LeRoith: Transcriptional repression of the insulin-like growth factor I receptor (IGF-I-R) gene by the tumor suppressor WT1 involves binding to sequences both upstream and downstream of the IGF-I-R gene transcription start site. J. Biol. Chem., 269:12577-12582 (1994).
174. Werner, H., G. G. Re, I. A. Drummond, V. P. Sukhatme, F. J. Rauscher, III, D. A. Sens, A. J. Garvin, D. LeRoith, and C. T. Roberts, Jr.: Increased expression of the insulinlike growth factor-I receptor gene, IGFIR, in Wilms' tumor is correlated with modulation of IGFIR promoter activity by the WT1 Wilms' tumor gene product. Proc. Natl. Acad. Sci. U.S.A., 90:5828-5832 (1993).
175. Werner, H., Z. Shen-Orr, F. J. Rauscher, III, J. F. Morris, C. T. Roberts, Jr., and D. LeRoith: Inhibition of cellular proliferation by the Wilms' tumor suppressor WT1 is associated with suppression of insulin-like growth factor I receptor gene expression. Mol. Cell. Biol., 15:3516-3522(1995).
176. Werner, H., B. Stannard, M. A. Bach, D. LeRoith, and C. T. Roberts, Jr.: Cloning and characterization of the proximal promoter region of the rat insulin-like growth factor I (IGF-I) receptor gene. Biochem. Biophys. Res. Comm., 169:1021-1027 (1990).
177. Werner, H., M. Woloschak, M. Adamo, Z. Shen-Orr, C. T. Roberts, Jr., and D. LeRoith: Developmental regulation of the rat insulin-like growth factor I receptor gene. Proc. Natl. Acad. Sci. U.S.A., 86:7451-7455 (1989).
178. Werner, H., M. Woloschak, B. Stannard, Z. Shen-Orr, C. T. Roberts, Jr., and D. LeRoith: Insulin-like growth factor receptor: molecular biology, heterogeneity, and regulation. In: Insulin-Like Growth Factors: Molecular and Cellular Aspects (LeRoith, D., Ed.) CRC Press, Boca Raton, FL, 17-47 (1991).
179. Williams, G. T. and C. A. Smith: Molecular regulation of apoptosis: genetic controls on cell death. Cell, 74:777-779 (1993).
180. Yee, D., S. Paik, G. S. Lebovic, R. R. Marcus, R. E. Favoni, K. J. Cullen, M. E. Lippman, and N. Rosen: Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol. Endocrinol, 3:509-514 (1989).
181. Yun, K., A. E. Fidler, M. R. Eccles, and A. E. Reeve: Insulinlike growth factor II and WT1 transcript localization in human fetal kidney and Wilms' tumor. Cancer Res., 53:5166-5171 (1993).
182. Zhang, J., J. M. Trent, and P. S. Meltzer: Rapid isolation and characterization of amplified DNA by chromosome microdissection: identification of IGFIR amplification in malignant melanoma. Oncogene, 8:2827-2831 (1993).
183. Zhang, L., F. Kashanchi, Q. Zhan, S. Zhan, J. N. Brady, A. J. Fornace, P. Seth, and L. J. Helman: Regulation of insulin-like growth factor II P3 promoter by p53: a potential mechanism for tumorigenesis. Cancer Res., 56:1367-1373 (1996)